REC-3565
B-cell malignancies
REC-3565 is a small molecule MALT1 inhibitor, being developed for multiple hematology indications. There are currently no MALT1 inhibitors approved by the FDA. The precision design of REC-3565 has resulted in a well-balanced molecule with selectivity over UGT1A1, which distinguishes it from other MALT1 inhibitors in clinical development. Avoiding UGT1A1 inhibition can potentially reduce hyperbilirubinemia risk and allow a better combination profile with drugs that have known liver toxicity issues.
Learn more on clinicaltrials.gov.
*Annual incidence of relapsed/refractory chronic lymphocytic leukemia and B-cell lymphomas. All populations defined above are US and EU5 incidence unless otherwise noted. EU5 is defined as France, Germany, Italy, Spain, and UK.
Case study
The challenge:
1
2
The unique how:
The outcome:
Learn more about clinical trial at Recursion.
Clinical trials
